

Benjamin Terrier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/771747/publications.pdf>

Version: 2024-02-01

172
papers

11,595
citations

53751

45
h-index

33869

99
g-index

179
all docs

179
docs citations

179
times ranked

18763
citing authors

#	ARTICLE	IF	CITATIONS
1	Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a caseâ€“control and exploratory study. <i>Rheumatology</i> , 2022, 61, 775-780.	0.9	11
2	The Clinical Spectrum and Outcome of Uveomeningitis: A Comprehensive Analysis of 110 Cases. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1489-1494.	1.0	2
3	Presentation, Diagnosis, and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases. <i>Chest</i> , 2022, 161, 257-265.	0.4	10
4	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
5	IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-Î± blockers. <i>Rheumatology</i> , 2022, 61, 1957-1965.	0.9	7
6	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2022, 61, 2464-2471.	0.9	8
7	Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. <i>Rheumatology</i> , 2022, 61, 865-867.	0.9	37
8	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€“linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. <i>British Journal of Haematology</i> , 2022, 196, 969-974.	1.2	85
9	Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis. <i>Rheumatology</i> , 2022, 61, 2619-2624.	0.9	5
10	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.5	26
11	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 550-556.e2.	1.5	25
12	Antiâ€“programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2022, 160, 134-139.	1.3	10
13	Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 681-684.	0.6	5
14	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.	2.5	8
15	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 720-728.	0.5	39
16	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. <i>Presse Medicale</i> , 2022, 51, 104107.	0.8	2
17	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. <i>BMC Nephrology</i> , 2022, 23, 67.	0.8	3
18	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
20	Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients. <i>Rheumatology</i> , 2022, 61, 3818-3823.	0.9	8
21	Optimising ANCA-associated vasculitis management and infectious risks during the COVID-19 pandemic. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 688-690.	0.4	0
22	Validation of anti-neutrophil cytoplasm antibodies associated vasculitides diagnosis codes from the electronic health records of two French university hospitals. <i>European Journal of Internal Medicine</i> , 2022, 103, 115-117.	1.0	3
23	Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study. <i>Rheumatology</i> , 2022, 61, e363-e365.	0.9	5
24	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. <i>Rheumatology</i> , 2022, 62, 341-346.	0.9	2
25	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Network Open</i> , 2022, 5, e2220925.	2.8	18
26	Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value. <i>Clinical Infectious Diseases</i> , 2021, 73, e2890-e2897.	2.9	92
27	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	0.9	21
28	Cutaneous Vasculitis: Review on Diagnosis and Clinicopathologic Correlations. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 181-193.	2.9	27
29	IgG4-related disease: From neck to brain. <i>Joint Bone Spine</i> , 2021, 88, 105041.	0.8	1
30	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	2.9	55
31	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 641-650.	2.9	8
32	Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis. <i>Autoimmunity Reviews</i> , 2021, 20, 102708.	2.5	20
33	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 719-720.	2.9	0
34	Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach. <i>Autoimmunity Reviews</i> , 2021, 20, 102707.	2.5	30
35	IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. <i>Journal of Rheumatology</i> , 2021, 48, 735-740.	1.0	7
36	Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A Case-Control Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 286-294.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 290-298.	1.0	4
38	Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 296-299.	1.7	16
39	Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 131-135.	1.0	8
40	Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. <i>Lancet Microbe</i> , The, 2021, 2, e60-e69.	3.4	78
41	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	1.8	14
42	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
43	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20
44	Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. <i>Nature Immunology</i> , 2021, 22, 322-335.	7.0	145
45	Venous thrombosis and predictors of relapse in eosinophil-related diseases. <i>Scientific Reports</i> , 2021, 11, 6388.	1.6	18
46	Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.7	10
47	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	1.6	22
48	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 436-441.	1.6	10
49	Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective caseâ€“noncase study. <i>Kidney International</i> , 2021, 99, 1235-1236.	2.6	19
50	Placental growth factor level in plasma predicts COVIDâ€™19 severity and inâ€“hospital mortality. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1823-1830.	1.9	28
51	Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides. <i>Journal of Clinical Medicine</i> , 2021, 10, 2299.	1.0	9
52	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
53	MO271PROGNOSIS OF NON-PR3 ANCA-ASSOCIATED VASCULITIDES WITH RENAL INVOLVEMENT. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
54	Mutant <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease. <i>New England Journal of Medicine</i> , 2021, 384, 2163-2165.	13.9	63

#	ARTICLE	IF	CITATIONS
55	Regulation of the acetylcholine/ α 7nAChR anti-inflammatory pathway in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 11886.	1.6	35
56	A role for IL-33-activated ILC2s in eosinophilic vasculitis. <i>JCI Insight</i> , 2021, 6, .	2.3	12
57	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021, , .	0.9	4
58	Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7462.	1.8	36
59	Platelet activation in critically ill COVID-19 patients. <i>Annals of Intensive Care</i> , 2021, 11, 113.	2.2	61
60	Atypical splice-site mutations causing VEXAS syndrome. <i>Rheumatology</i> , 2021, 60, e435-e437.	0.9	40
61	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1489-1499.	1.9	32
62	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. <i>Autoimmunity Reviews</i> , 2021, 20, 102874.	2.5	2
63	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. <i>Science Advances</i> , 2021, 7, .	4.7	27
64	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. <i>Nature Immunology</i> , 2021, 22, 1428-1439.	7.0	110
65	Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality. <i>Arthritis and Rheumatology</i> , 2021, 73, 1976-1985.	2.9	21
66	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. <i>Angiogenesis</i> , 2021, 24, 505-517.	3.7	105
67	Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome. <i>Seminars in Hematology</i> , 2021, 58, 247-253.	1.8	9
68	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	2.7	3
69	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1665-1675.	2.2	8
70	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, , .	2.7	8
71	Comment on: Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study: reply. <i>Rheumatology</i> , 2021, , .	0.9	2
72	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 155-160.	0.4	3

#	ARTICLE	IF	CITATIONS
73	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 155-160.	0.4	10
74	Serum 1,25(OH) ₂ Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 341-347.	1.0	11
75	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. <i>Journal of Autoimmunity</i> , 2020, 106, 102338.	3.0	43
76	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	1.0	10
77	Risk of malignancy in patients treated for systemic necrotising vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 431-433.	0.5	7
78	Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. <i>Science</i> , 2020, 369, 718-724.	6.0	2,374
79	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
80	IgA monoclonal gammopathy associated with refractory IgA vasculitis successfully treated with clone-targeted therapy. <i>Autoimmunity Reviews</i> , 2020, 19, 102611.	2.5	3
81	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	2.0	116
82	Chronic obstructive pulmonary disease associated with hypocomplementemic urticarial vasculitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3222-3224.e1.	2.0	4
83	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	1.6	21
84	Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	37
85	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
86	Role of therapeutic plasma exchanges in systemic vasculitis. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102992.	0.5	6
87	Cardiac Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 1571-1580.	2.9	24
88	Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database. <i>Journal of Rheumatology</i> , 2020, 47, 1298-1300.	1.0	4
89	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. <i>Neurology</i> , 2020, 95, e70-e78.	1.5	142
90	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , 2020, 369, m1844.	3.0	355

#	ARTICLE	IF	CITATIONS
91	Angiotensin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. <i>Angiogenesis</i> , 2020, 23, 611-620.	3.7	204
92	Risk of scleroderma according to the type of immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102596.	2.5	44
93	ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. <i>Presse Medicale</i> , 2020, 49, 104031.	0.8	21
94	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	2.5	36
95	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. <i>Journal of Autoimmunity</i> , 2020, 112, 102467.	3.0	25
96	Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. <i>Rheumatology</i> , 2020, 59, iii84-iii94.	0.9	53
97	A meal served cold. <i>British Journal of Haematology</i> , 2020, 190, 12-12.	1.2	1
98	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4</i>	1.2	39
99	Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Joint Bone Spine</i> , 2019, 86, 273-274.	0.8	0
100	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019, 14, 1193-1197.	1.0	13
101	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
102	Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1446-1448.	0.5	8
103	Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. <i>Rheumatology</i> , 2019, 58, 1565-1573.	0.9	28
104	Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. <i>Autoimmunity Reviews</i> , 2019, 18, 493-500.	2.5	43
105	117.â€fPREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURGâ€“ STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
106	THU0001â€...CIRCULATING INNATE LYMPHOID CELLS IN IGG4-RELATED DISEASE. , 2019, , .		0
107	Gastrointestinal Behcetâ€™s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	0.6	22
108	Maintenance of Remission in antineutrophil cytoplasm antibodyâ€associated vasculitides. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 100-104.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. <i>Rheumatology</i> , 2019, 58, 401-409.	0.9	35
110	Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 130-136.	0.4	2
111	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	2.0	56
112	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1150-1156.	0.5	139
113	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1143-1149.	0.5	219
114	Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. <i>Oncolmmunology</i> , 2018, 7, e1450712.	2.1	4
115	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212705.	0.5	38
116	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	2.5	42
117	Diversification of human plasmacytoid predendritic cells in response to a single stimulus. <i>Nature Immunology</i> , 2018, 19, 63-75.	7.0	106
118	Treatment of Pulmonary Vasculitis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 504-510.	0.8	0
119	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	1.0	29
120	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 984-989.	2.5	15
121	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	0.9	38
122	Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 504-511.	2.5	46
123	Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	2.9	117
124	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 872-872.	2.9	1
125	Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. <i>Autoimmunity Reviews</i> , 2017, 16, 1138-1146.	2.5	32
126	A Severe But Easily Treatable Dysphagia. <i>Gastroenterology</i> , 2017, 153, e9-e10.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. <i>Arthritis and Rheumatology</i> , 2017, 69, 2175-2186.	2.9	117
128	Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. <i>Autoimmunity Reviews</i> , 2017, 16, 1036-1043.	2.5	120
129	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 963-969.	2.5	70
130	Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study. <i>Joint Bone Spine</i> , 2017, 84, 643-644.	0.8	10
131	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	1.1	174
132	Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 222.	0.4	0
133	Letter to the Editor: Central Nervous System Involvement in Relapsing Polychondritis, a Rare and Difficult Diagnosis: a Case Report. <i>Journal of Korean Medical Science</i> , 2017, 32, 1048.	1.1	1
134	Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 40-46.	0.4	9
135	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 176-184.	0.4	7
136	Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 2274-2282.	2.9	84
137	Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. <i>Rheumatology</i> , 2016, 56, kew423.	0.9	3
138	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 141.	1.2	62
139	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	2.9	101
140	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	3.0	44
141	Efficacy of colchicine in a child with relapsing bullous Henoch-Schönlein purpura. <i>European Journal of Pediatrics</i> , 2016, 175, 147-149.	1.3	15
142	Can Rituximab be Useful for Treating SLE-Associated Immune Cytopenias ? Results from a Retrospective Multicentre Study on 62 Patients. <i>Blood</i> , 2016, 128, 870-870.	0.6	1
143	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	1.1	19
144	Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's). <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62</i>	0.4	53

#	ARTICLE	IF	CITATIONS
145	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. <i>Rheumatology</i> , 2015, 54, 1852-1857.	0.9	38
146	IgA vasculitis (Henoch-Schönlein purpura) in adults: Diagnostic and therapeutic aspects. <i>Autoimmunity Reviews</i> , 2015, 14, 579-585.	2.5	187
147	Atypical Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Medicine</i> , 2015, 128, e47-e49.	0.6	5
148	Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. <i>Autoimmunity Reviews</i> , 2015, 14, 996-1004.	2.5	50
149	Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. <i>Autoimmunity Reviews</i> , 2015, 14, 774-780.	2.5	37
150	Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature. <i>Journal of Autoimmunity</i> , 2015, 65, 74-81.	3.0	76
151	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015, 65, 49-55.	3.0	34
152	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. <i>Rheumatology</i> , 2015, 54, 424-432.	0.9	89
153	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e86-e87.	0.9	1
154	Factors Associated with Major Cardiovascular Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study. <i>Journal of Rheumatology</i> , 2014, 41, 723-729.	1.0	25
155	Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. <i>Journal of Autoimmunity</i> , 2014, 50, 135-141.	3.0	67
156	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	2.5	23
157	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	0.9	67
158	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	0.8	62
159	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. <i>American Journal of Cardiology</i> , 2013, 111, 265-272.	0.7	43
160	Renal involvement in HCV-related vasculitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 334-339.	0.7	26
161	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 374-380.	0.5	59
162	The Spectrum of Type I Cryoglobulinemia Vasculitis. <i>Medicine (United States)</i> , 2013, 92, 61-68.	0.4	150

#	ARTICLE	IF	CITATIONS
163	Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1819-1828.	1.0	100
164	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 756-761.	1.8	89
165	Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3577-3581.	0.4	13
166	Systemic Vasculitis in Patients with Hepatitis C Virus Infection with and without Detectable Mixed Cryoglobulinemia. <i>Journal of Rheumatology</i> , 2011, 38, 104-110.	1.0	23
167	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. <i>Blood</i> , 2010, 116, 4523-4531.	0.6	126
168	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
169	Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a caseâ€“control study from a single-centre cohort of 163 patients. <i>Gut</i> , 2010, 59, 1709-1715.	6.1	28
170	Cerebral Vasculopathy Is Associated with Severe Vascular Manifestations in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1486-1494.	1.0	28
171	Efficacy and tolerability of rituximab with or without PEGylated interferon alfaâ€“2b plus ribavirin in severe hepatitis C virusâ€“related vasculitis: A longâ€“term followup study of thirtyâ€“two patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 2531-2540.	6.7	99
172	Remission and Lowâ€“Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual. <i>Arthritis Care and Research</i> , 0, , .	1.5	2